연구동향 분석
박사

The oncogenic role of mitogen-inducible gene 6 (Mig-6) in lung adenocarcinoma with EGFR mutation

강다현 2019년

논문상세정보
    • 저자 강다현
    • 기타서명 EGFR 돌연변이를 가진 폐선암에서 Mig-6의 역할
    • 형태사항 26 cm: 55 p.
    • 일반주기 충남대학교 논문은 저작권에 의해 보호받습니다, 지도교수: 김주옥, 참고문헌 : p. 46-52
    • 학위논문사항 학위논문(박사)-, 2019. 2, 忠南大學校 大學院, 의학과 내과학 전공
    • DDC 22, 616
    • 발행지 대전
    • 언어 kor
    • 출판년 2019
    • 발행사항 忠南大學校 大學院
    유사주제 논문( 1,834)
인용/피인용
' The oncogenic role of mitogen-inducible gene 6 (Mig-6) in lung adenocarcinoma with EGFR mutation' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • 질병
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
1,198 0

0.0%

' The oncogenic role of mitogen-inducible gene 6 (Mig-6) in lung adenocarcinoma with EGFR mutation' 의 참고문헌

  • Zhang Z, Stiegler AL, Boggon TJ, Kobayashi S, Halmos B. EGFRmutated lung cancer: a paradigm of molecular oncology. Oncotarget. 2010;1(7):497.
  • Zhang Y-W, Staal B, Su Y-l, Swiatek P, Zhao P, Cao B, et al. Evidence that MIG-6 is a tumor-suppressor gene. Oncogene. 2007;26(2):269.
  • Zhang X, Pickin KA, Bose R, Jura N, Cole PA, Kuriyan J. Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface. Nature. 2007;450(7170):741.
  • Zhang X, Pickin KA, Bose R, Jura N, Cole PA, Kuriyan J. Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface. Nature. 2007;450(7170):741-4.
  • Yu H, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, et al. Analysis of Mechanisms of Acquired Resistance to EGFR TKI therapy in 155 patients with EGFR-mutant Lung Cancers. Clinical cancer research. 2013:clincanres. 2246.012.
  • Ying H, Zheng H, Scott K, Wiedemeyer R, Yan H, Lim C, et al. Mig- 6 controls EGFR trafficking and suppresses gliomagenesis. Proceedings of the National Academy of Sciences. 2010;107(15):6912-7.
  • Xu Z, Hang J, Hu J, Gao B. Gefitinib, an EGFR tyrosine kinase inhibitor, activates autophagy through AMPK in human lung cancer cells. J BUON. 2014;19(2):466-73.
  • Sui X, Kong N, Zhu M, Wang X, Lou F, Han W, et al. Cotargeting EGFR and autophagy signaling: A novel therapeutic strategy for non-smallcell lung cancer. Mol Clin Oncol. 2014;2(1):8-12.
  • Steuer CE, Khuri FR, Ramalingam SS. The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer. Cancer. 2015;121(8):E1-E6.
  • Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3(75):75ra26.
  • Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2000;103(2):211-25.
  • Sakuma Y, Matsukuma S, Nakamura Y, Yoshihara M, Koizume S, Sekiguchi H, et al. Enhanced autophagy is required for survival in EGFRindependent EGFR-mutant lung adenocarcinoma cells. Lab Invest. 2013;93(10):1137-46.
  • Park E, Kim N, Ficarro SB, Zhang Y, Lee BI, Cho A, et al. Structure and mechanism of activity-based inhibition of the EGF receptor by Mig6. Nature Structural and Molecular Biology. 2015;22(9):703.
  • Oxnard GR, Arcila ME, Sima CS, Riely GJ, Chmielecki J, Kris MG, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clinical cancer research. 2011;17(6):1616-22.
  • Ogiso H, Ishitani R, Nureki O, Fukai S, Yamanaka M, Kim J-H, et al. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell. 2002;110(6):775-87.
  • Network CGAR. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511(7511):543.
  • Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, et al. Cancer treatment and survivorship statistics, 2016. CA: a cancer journal for clinicians. 2016;66(4):271-89.
  • McCubrey JA, Steelman LS, Bertrand FE, Davis NM, Sokolosky M, Abrams SL, et al. GSK-3 as potential target for therapeutic intervention in cancer. Oncotarget. 2014;5(10):2881.
  • Maity TK, Venugopalan A, Linnoila I, Cultraro CM, Giannakou A, Nemati R, et al. Loss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptor-Driven Lung Adenocarcinoma. Cancer Discov. 2015;5(5):534-49.
  • Liu T-A, Jan Y-J, Ko B-S, Liang S-M, Chen S-C, Wang J, et al. 14-3- 3ε overexpression contributes to epithelial-mesenchymal transition of hepatocellular carcinoma. PloS one. 2013;8(3):e57968.
  • Lin Y, Wang X, Jin H. EGFR-TKI resistance in NSCLC patients: mechanisms and strategies. American journal of cancer research. 2014;4(5):411.
  • Leighl N. Treatment paradigms for patients with metastatic nonsmall- cell lung cancer: first-, second-, and third-line. Current oncology. 2012;19(Suppl 1):S52.
  • Lee JE, Park HS, Lee D, Yoo G, Kim T, Jeon H, et al. Hippo pathway effector YAP inhibition restores the sensitivity of EGFR-TKI in lung adenocarcinoma having primary or acquired EGFR-TKI resistance. Biochem Biophys Res Commun. 2016;474(1):154-60.
  • Lee BS, Park DI, Lee DH, Lee JE, Yeo MK, Park YH, et al. Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFRTKI- resistant lung adenocarcinoma. Biochem Biophys Res Commun. 2017;491(2):493-9.
  • Kim MH, Kim CG, Kim SK, Shin SJ, Choe EA, Park SH, et al. YAPInduced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma. Cancer Immunol Res. 2018.
  • Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013;502(7471):333.
  • Izumchenko EG, Chang X, Michailidi C, Kagohara LT, Ravi R, Paz K, et al. The TGFβ-miR200-MIG6 pathway orchestrates the EMT-associated kinase switch that induces resistance to EGFR inhibitors. Cancer research. 2014:canres. 0110.2014.
  • Izumchenko E, Sidransky D. Understanding the MIG6-EGFR Signaling Axis in Lung Tumorigenesis. Cancer Discov. 2015;5(5):472-4.
  • Izumchenko E, Chang X, Michailidi C, Kagohara L, Ravi R, Paz K, et al. The TGFbeta-miR200-MIG6 pathway orchestrates the EMT-associated kinase switch that induces resistance to EGFR inhibitors. Cancer Res. 2014;74(14):3995-4005.
  • Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO, et al. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor α. Cell. 2002;110(6):763-73.
  • Frosi Y, Anastasi S, Ballar C, Varsano G, Castellani L, Maspero E, et al. A two-tiered mechanism of EGFR inhibition by RALT/MIG6 via kinase suppression and receptor degradation. The Journal of cell biology. 2010;189(3):557-71.
  • Ferby I, Reschke M, Kudlacek O, Knyazev P, Pant G, Amann K, et al. Mig6 is a negative regulator of EGF receptor–mediated skin morphogenesis and tumor formation. Nature medicine. 2006;12(5):568.
  • Endo H, Okami J, Okuyama H, Nishizawa Y, Imamura F, Inoue M. The induction of MIG6 under hypoxic conditions is critical for dormancy in primary cultured lung cancer cells with activating EGFR mutations. Oncogene. 2017;36(20):2824-34.
  • Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer discovery. 2014:CD-14- 0337.
  • Chung C, Yoo G, Kim T, Lee D, Lee CS, Cha HR, et al. The E3 ubiquitin ligase CHIP selectively regulates mutant epidermal growth factor receptor by ubiquitination and degradation. Biochem Biophys Res Commun. 2016;479(2):152-8.
  • Chmielecki J, Foo J, Oxnard GR, Hutchinson K, Ohashi K, Somwar R, et al. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med. 2011;3(90):90ra59.
  • Chang X, Izumchenko E, Solis LM, Kim MS, Chatterjee A, Ling S, et al. The relative expression of Mig6 and EGFR is associated with resistance to EGFR kinase inhibitors. PLoS One. 2013;8(7):e68966.
  • Bachelder RE, Yoon S-O, Franci C, de Herreros AG, Mercurio AM. Glycogen synthase kinase-3 is an endogenous inhibitor of Snail transcription: implications for the epithelial–mesenchymal transition. The Journal of cell biology. 2005;168(1):29-33.
  • Anastasi S, Baietti MF, Frosi Y, Alema S, Segatto O. The evolutionarily conserved EBR module of RALT/MIG6 mediates suppression of the EGFR catalytic activity. Oncogene. 2007;26(57):7833-46.
  • Anagnostou VK, Brahmer JR. Cancer immunotherapy: a future paradigm shift in the treatment of non–small cell lung cancer. Clinical Cancer Research. 2015;21(5):976-84.